Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

Targeting CB1 receptors is not a new concept in the biotech and pharma worlds ... and in combination with Eli Lilly's (LLY) Zepbound (tirzepatide). Scholar Rock (NASDAQ:SRRK) CEO Jay Backstrom ...

With Robert F. Kennedy Jr. set to be sworn in as HHS secretary later Thursday, one of the first tasks in his new position will be to implement some of the ideas spelled out in his "Make America Health ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech hub ... evidence study involving tirzepatide, the dual GIP/GLP ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...